In the cases provided for in Article L. 1241-5, the Minister for Research may suspend or prohibit implementation of the protocol under the conditions described in Articles R. 1232-18 and R. 1232-22. The decision to suspend or prohibit is communicated to the Director General of the Agence de la biomédecine.